Cancer Research
HDAC Inhibitor Plus Checkpoint Blocker Tested in Advanced Lung Cancer Trial
A phase 1/2 trial combined mocetinostat and durvalumab in 83 patients with advanced solid tumors and NSCLC.
Clinical Trial
May 7, 2026 0
Results for "Quercetin Senolytic" in Cancer
20 articles
Cancer Research
Pfizer Tests Novel CD47-PD-L1 Bispecific Antibody in Advanced Solid Tumors
A first-in-human Phase 1 trial evaluates PF-07257876, a dual-checkpoint bispecific antibody targeting both CD47 and PD-L1, in hard-to-treat cancers.
Clinical Trial
May 21, 2026 0
Cancer Research
Curcumin Added to Standard Chemo Tested in Metastatic Colorectal Cancer Trial
A Phase 2 trial explores whether oral curcumin can enhance Avastin/FOLFIRI chemotherapy outcomes in patients with unresectable colorectal metastases.
Clinical Trial
May 16, 2026 0
Cancer Research
Triple Combo Therapy Targets Chemo-Resistant Colorectal Cancer in Phase I Trial
A completed phase I trial tests regorafenib plus dual checkpoint inhibitors in 39 patients with hard-to-treat metastatic colorectal cancer.
Clinical Trial
May 9, 2026 0
Cancer Research
Triple Combination Cancer Immunotherapy Shows Promise in Advanced Solid Tumors
Small trial tests novel three-drug approach combining immune checkpoint inhibitor, vaccine, and inflammation blocker for metastatic cancers.
Clinical Trial
Mar 29, 2026 1
Cancer Research
Cancer Trial Tests Novel Immune Booster BAY 2416964 With Pembrolizumab
Researchers tested a new drug combination targeting immune suppression in advanced solid tumors before early termination.
Clinical Trial
Mar 28, 2026 0
Cancer Research
Triple Immune Checkpoint Blockade Tested in Advanced Solid Tumors
A Phase 1/2 trial explores combining KIR, PD-1, and CTLA-4 inhibitors to unlock stronger anti-tumor immunity.
Clinical Trial
May 20, 2026 0
Cancer Research
NCI Trial of Dual Immunotherapy Bintrafusp Alfa for Bladder Cancer Terminated Early
A Phase II NCI trial testing bintrafusp alfa in metastatic urothelial carcinoma was terminated after enrolling only 2 patients.
Clinical Trial
May 21, 2026 0
Cancer Research
Metronomic Vinorelbine Plus Atezolizumab Tested as Second-Line NSCLC Therapy
A completed Phase 2 trial explores whether low-dose continuous chemotherapy can boost immunotherapy efficacy in advanced lung cancer.
Clinical Trial
Jun 9, 2026 0
Cancer Research
Dual Checkpoint Blockade Plus FOLFOX Chemo Tested in Metastatic Colorectal Cancer
A Phase 1/2 trial tests whether combining durvalumab, tremelimumab, and FOLFOX chemotherapy can safely boost immune response in mCRC.
Clinical Trial
May 17, 2026 0
Cancer Research
Triple Drug Combo Targets Richter's Syndrome in Completed Phase 2 Trial
A phase 2 trial tests obinutuzumab, ibrutinib, and venetoclax in Richter's syndrome, a deadly CLL transformation with few treatment options.
Clinical Trial
Jun 4, 2026 0
Cancer Research
Triple Immunotherapy Combo for Recurrent SCLC Terminated After Enrolling 9 Patients
A phase I/II trial combining nivolumab, ipilimumab, and lurbinectedin for relapsed SCLC was terminated early, raising questions about feasibility.
Clinical Trial
May 16, 2026 0
Cancer Research
Apalutamide Plus Immunotherapy Combo Trial for Rare Prostate Cancer Variant Terminated
A Phase 2 trial testing AR blockade combined with PD-1 inhibition in treatment-emergent neuroendocrine prostate cancer was terminated early.
Clinical Trial
May 15, 2026 0
Cancer Research
Abraxane Plus Pembrolizumab Targets Advanced Bladder Cancer in Cisplatin-Ineligible Patients
A completed phase 2 trial tested nab-paclitaxel combined with the checkpoint inhibitor pembrolizumab in patients with advanced urothelial cancer who cannot tolerate cisplatin.
Clinical Trial
Jul 1, 2026 0
Cancer Research
Melanoma Drug Resistance Linked to Cellular Communication Vesicles Called Exosomes
French researchers studied how tiny cellular packages called exosomes may help melanoma cells resist treatment and spread throughout the body.
Clinical Trial
Mar 28, 2026 0
Cancer Research
Natural Killer Cell Therapy Shows Promise for Advanced Cancer Treatment
Autologous NK cell therapy combined with immunotherapy tested in 27 patients with treatment-resistant cancers.
Clinical Trial
Mar 29, 2026 0
Cancer Research
Pfizer Terminates Phase 1 Trial of Novel Anti-PD-1/IL-15 Fusion Protein in Solid Tumors
Pfizer's first-in-human trial of PF-07209960, a dual-action immunotherapy fusion protein, was terminated after enrolling 37 patients.
Clinical Trial
May 14, 2026 0
Cancer Research
Cancer Vaccine OSE2101 Tested Against Standard Chemotherapy in Advanced Lung Cancer
Phase 3 trial compared therapeutic vaccine OSE2101 to chemotherapy in 219 lung cancer patients after immunotherapy failure.
Clinical Trial
Mar 28, 2026 0
Cancer Research
PULSAR Radiation Plus IMSA101 Immunotherapy Trial in Oligoprogressive Cancers Terminated Early
A Phase 2 trial combining adaptive stereotactic radiotherapy with IMSA101 and checkpoint inhibitors was halted after enrolling only 16 patients.
Clinical Trial
May 14, 2026 0
Cancer Research
L-Arginine Tested to Restore Erectile Function in Prostate Cancer Radiation Survivors
A phase II trial explores whether the amino acid L-arginine, with or without enzyme inhibitors, can improve erectile function and quality of life after prostate cancer radiation therapy.
Clinical Trial
May 29, 2026 0
Page 1 of 2Next